The first trial on volunteers of an anti-virus vaccine against the novel coronavirus has begun in the United States. It is based on the re-engineering of our cell’s messengerRNA, (Ed.One word) which is a biological wonder. The initiative in this direction was led by India and Norway, some four years ago at the World Economic Forum. Experts say the potential of the wonder is far from being fully utilised, even as the results of the trial are anxiously awaited.
The clinical trial began at the Kaiser Permanente Washington Health Research Institute in Seattle (U.S.A.) as the first volunteer received the investigational vaccine. The trial is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants aged 18-55. This is significant as currently, no approved vaccine exists to prevent infection with SARS-CoV-2. The result of the vaccine under trial is expected in a few....
